MSD has fleshed out its cardiovascular disease pipeline by licensing an oral Lp(a) inhibitor from China's Jiangsu Hengrui Pharma for $200 million upfront. The deal gives MSD exclusive rights to ...

MSD has expanded its presence in Ireland with an agreement to buy a vaccine manufacturing facility from Chinese biotech WuXi Biologics for around €500 million (around $520 million). The plant in ...

One of the main factors determining therapeutic antibodies’ half-life is the interaction between the antibody’s Fc region and ...